FIELD: medicine.
SUBSTANCE: invention is related to the field of genetic research, molecular biology, clinical biochemistry, medicine, veterinary science, pharmacology, endocrinology. Method includes combined determination of activity of serine proteinase-hepsin and methylated gene glutathione-8-transferase of class P1 (GSTP1) in tumour cells detected in patients urine, and if hepsin activity is more than 42% relative to control and detection of methylated gene GSTP1, oncological disease is diagnosed.
EFFECT: provides for differential diagnostics of prostate, such as prostate adenoma (innocent hyperplasia), prostatitis, prostatic intraepithelial hyperplasia, prostate cancer, and provides for non-invasiveness and increased possibility of correct diagnosis.
4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR PROSTATE CANCER | 2012 |
|
RU2521389C2 |
| METHOD FOR EARLY DIAGNOSIS OF PROSTATE TUMORS | 2021 |
|
RU2756643C1 |
| MARKER OF PROSTATE GLAND CANCER | 2007 |
|
RU2360924C1 |
| EARLY DNA-DIAGNOSTIC TECHNIQUE OF PROSTATE CANCER | 2009 |
|
RU2405837C1 |
| DIAGNOSTIC TECHNIQUE FOR PROSTATE CANCER | 2011 |
|
RU2464574C1 |
| METHOD OF DETERMINING THE RISK OF MALIGNANT TRANSFORMATION OF PROSTATE CELLS | 2022 |
|
RU2806518C1 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR PROSTATE CANCER | 2011 |
|
RU2469333C1 |
| METHOD FOR ESTABLISHING INDICATIONS FOR PROSTATE BIOPSY | 2009 |
|
RU2406446C1 |
| METHOD FOR PREDICTION OF AGGRESSIVE FORMS OF PROSTATE CANCER IN PATIENTS OF INTERMEDIATE AND HIGH RISK GROUP | 2021 |
|
RU2768477C1 |
| DIAGNOSTIC TECHNIQUE FOR PROSTATE CANCER | 2015 |
|
RU2607949C1 |
